ÌÇÐÄvlog´«Ã½

Cell Therapy Market Analysis

The Cell Therapy Market size is estimated at USD 4.77 billion in 2024, and is expected to reach USD 7.56 billion by 2029, growing at a CAGR of 17.05% during the forecast period (2024-2029).

The cell therapy market is anticipated to experience significant growth driven by the growing incidence of chronic diseases, a growing acceptance of regenerative medicine, and an increase in clinical research focused on cellular therapy advancements.

The rising burden of chronic diseases and other health conditions across the world fuels the need for cell therapy, thus driving the growth of the market. For instance, in June 2023, as per the Institute for Health Metrics and Evaluation, approximately 500 million adults around the world were diagnosed with diabetes, and this figure is projected to rise to 1.3 billion by 2050. Additionally, the data published by the World Health Organization in February 2024 mentioned that it is anticipated that there will be over 35 million new cancer cases, which represents a 77% rise from the estimated 20 million cases in 2022 globally. As a result, the rising prevalence of chronic conditions fuels the demand for different cell therapies in their treatment and is expected to drive the industry's growth.

Furthermore, product approvals, collaborations, and a rise in clinical studies focused on the development of cellular therapies are expected to propel the market's growth during the forecast period. For instance, in October 2023, Caribou Biosciences Inc. obtained approval from the Food and Drug Administration (FDA) for an investigational new drug application for allogeneic anti–CLL–1 chimeric antigen receptor (CAR) T Cell therapy CB-012 indicated for the treatment of patients with relapsed/refractory acute myeloid leukemia (AML). Moreover, in April 2023, Seattle Children's Therapeutics introduced a first-in-human phase-1 clinical trial, BrainChild-04, a chimeric antigen receptor (CAR) T-cell clinical trial targeting four antigens at the same time to address the needs of children, teens, and young adults with diffuse intrinsic pontine glioma (DIPG), diffuse midline glioma (DMG), and other brain and spinal cord tumors. Hence, such developments associated with cell therapies are likely to increase product availability and competition, which contributes to the market's growth during the forecast period.

Thus, the rising burden of chronic diseases and increasing product approvals and clinical trials are expected to positively influence the market's growth during the forecast period. However, the high cost associated with cell therapies is expected to hinder the market's growth.

Cell Therapy Industry Segmentation

As per the scope of the report, cell therapy is known as a type of therapy in which live cells are injected into a patient for the treatment of a number of disorders by replacing diseased or dysfunctional cells with healthy functioning ones. Some of the cells used for the treatment include hematopoietic (blood-forming) stem cells (HSC), skeletal muscle stem cells, mesenchymal stem cells, lymphocytes, dendritic cells, and pancreatic islet cells. 

The cell therapy market is segmented by type, therapy, application, and geography. By type, the market is segmented into autologous and allogeneic. By therapy, the market is segmented into mesenchymal stem cell therapy, fibroblast cell therapy, hematopoietic stem cell therapy, and other therapies. By application, the market is segmented into musculoskeletal, malignancies, cardiovascular, dermatology and wounds, and other applications. By geography, the market is segmented into North America, Europe, Asia-Pacific, Middle East and Africa, and South America. The market size is provided for each segment in terms of value (USD).